CARCINOMA, OVARIAN EPITHELIAL
Clinical trials for CARCINOMA, OVARIAN EPITHELIAL explained in plain language.
Never miss a new study
Get alerted when new CARCINOMA, OVARIAN EPITHELIAL trials appear
Sign up with your email to follow new studies for CARCINOMA, OVARIAN EPITHELIAL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Ovarian cancer combo shows promise in maintenance therapy
Disease control OngoingThis phase IV trial tests whether the drugs olaparib and bevacizumab, taken together after initial chemotherapy, can help prevent ovarian cancer from coming back in women with a specific genetic marker (HRD-positive). About 190 participants who have already responded to first-lin…
Matched conditions: CARCINOMA, OVARIAN EPITHELIAL
Phase: PHASE4 • Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Ovarian cancer hope: new antibody combo aims to delay disease worsening
Disease control OngoingThis Phase 3 trial tests whether adding an experimental antibody called oregovomab to standard chemotherapy (paclitaxel and carboplatin) helps people with newly diagnosed advanced ovarian cancer live longer without their cancer getting worse. About 615 participants who had surger…
Matched conditions: CARCINOMA, OVARIAN EPITHELIAL
Phase: PHASE3 • Sponsor: CanariaBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Ovarian cancer trial hopes immunotherapy can buy more time
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel, with or without bevacizumab) can slow the growth of ovarian cancer that has become resistant to platinum-based treatments. About 643 adults with recurrent ovarian, fallopian…
Matched conditions: CARCINOMA, OVARIAN EPITHELIAL
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo takes on advanced cancers in early trial
Disease control OngoingThis early-stage trial is testing a new drug called KFA115, either by itself or combined with the immunotherapy Keytruda (pembrolizumab), in 126 people with advanced cancers like lung, skin, kidney, and others. The main goal is to check safety and find the best dose. It is not ye…
Matched conditions: CARCINOMA, OVARIAN EPITHELIAL
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC